Coherus Oncology, Inc.CHRS

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · coherus.com

Coherus Oncology is a commercial-stage immuno-oncology company built around the approved next-generation PD-1 inhibitor LOQTORZI (toripalimab-tpzi). Its pipeline includes casdozokitug, an IL-27 antagonist antibody in Phase 2 for hepatocellular carcinoma, and tagmokitug (CHS-114), a selective anti-CCR8 antibody in Phase 1b/2a for advanced solid tumours. The company was named Coherus BioSciences until its 2026 rebrand; the CHRS symbol is unchanged.

Key ratios

FCF / Sales

-365.2%TTM

2025 -328.4%2024 -77.5%2023 -68.0%

Net margin

-259.4%TTM

2025 398.4%2024 108.0%2023 -92.5%

ROA

-30.5%TTM

2025 -31.2%2024 -21.9%2023 -21.8%

ROE

-178.4%TTM

Revenue growth

61.0%TTM

2025 59.8%2024 -89.7%2023 21.9%

Recent news

Coherus to Participate in Upcoming Investor Conferences 2026-08-31 · GlobeNewswire Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights 2026-08-17 · GlobeNewswire

Track CHRS in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer